Self-StudyKey Populations
You are just a few steps away from free CE credits!
Sign in or Register
A free account is required.
Study the Material
An entire Cc section, or just a few topics at a time.
Take the CE Quiz
5 questions covering the topics in each Cc section.
Claim CE Credit
Free CNE and Free CME available!
- Lesson 1 Overview
HIV in Infants and Children - 0%Topic 1
IntroductionActivities- 0%Topic 2
Epidemiology of HIV in Children Younger than Age 13Activities- 0%Topic 3
Staging of Pediatric HIV DiseaseActivities- 0%Topic 4
Diagnosis of HIV in Infants and ChildrenActivities- 0%Topic 5
Clinical and Laboratory MonitoringActivities- 0%Topic 6
Antiretroviral Treatment for Children with HIVActivities- 0%Topic 7
Immunizations for Children Living with HIVHIV in Infants and Children Overview
About this Lesson
Last Updated: February 3rd, 2025CNE/CME Continuing Education
This lesson qualifies for:- 1.5 CME AMA PRA Category 1 Credits™, or
- 1.5 CNE contact hours and 1.5 CE contact hours (qualifies for pharmacology CE for advanced practice nurses)
CNE and CME Origination: September 17th, 2018CNE and CME Review: September 1st, 2023CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE NoticesSteps to Acquire CE for this Lesson:
3Print CE Certificate
Obtain proof of CE3rd Edition
This is a substantial revision of the original Lesson. The previous edition was titled HIV in Infants and Children and available until September 1st, 2023.Learning Objectives
- Discuss basic epidemiologic features of perinatally-acquired HIV and pediatric HIV in the United States
- Explain the timing and types of diagnostic tests used to diagnose HIV in infants less than 1 year of age and in older children
- List symptoms and classification of HIV in children using the most recent CDC surveillance case definition for pediatric HIV
- Summarize antiretroviral therapy management in children, including initiation, adverse effects, and approach to virologic failure
- Discuss opportunistic infection prevention recommendations for infants and children and how these recommendations are influenced by a child’s age and stage of HIV
Lesson Contributors
Authors
Aley G. Kalapila, MD, PhDAley G. Kalapila, MD, PhD
Professor of Medicine
Division of Infectious Diseases
Emory University School of Medicine
Grady Health SystemDisclosures:NoneDavid H. Spach, MDDavid H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneReviewers
Ann J Melvin, MD, MPHAnn J Melvin, MD, MPH
Professor of Pediatrics
Division of Pediatric Infectious Disease
Seattle Children’s Hospital
University of WashingtonDisclosures:Grants to institutions: MerckThe relevant financial relationship was mitigated.Lesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Question Bank
Interactive board-review style questions about Epidemiology of HIV.
CNE/CME CME+MOC credits and CNE contact hours available.
Requires sign-in for CE credit or Certificates
Funded byHealth Resources and Services Administration (HRSA)Created at University of WashingtonAn AETC ProgramPart of IDEA PlatformCME provided byUniversity of Alabama BirminghamCNE approved byOregon Nurses AssociationCopyright © 2025 National HIV CurriculumThe Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,994. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-d52d2330-2025-09-05-201745 - 0%Topic 2
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant